HUTCHMED (China) Ltd (STU:H7T1)
€ 16.1 0.5 (3.21%) Market Cap: 2.75 Bil Enterprise Value: 2.08 Bil PE Ratio: 0 PB Ratio: 4.11 GF Score: 64/100

HUTCHMED (China) Ltd FRESCO-2 Data at ESMO Call Transcript

Sep 12, 2022 / 12:00PM GMT
Release Date Price: €13.2 (+5.60%)
Operator

Good evening, afternoon, and morning. Welcome to HUTCHMED Conference Call and Webcast. (Operator Instructions) Please be advised that this call will be recorded. I'll turn the call over to your first speaker today, Dr. Weiguo Su, Chief Executive Officer and Chief Scientific Officer of HUTCHMED. Please go ahead, sir.

Weiguo Su;China;Limited;CEO
HUTCHMED;Chief Scientific Officer & Executive Director

()- -

Thank you. Welcome, everyone. This is the FRESCO-2 Phase III trial conference call. A couple of hours ago, we just presented the Phase III top line results at ESMO. I understand the presentation time was the most friendly for folks in the U.S. So we are privileged today to have the steering committee of the study members on the call to give another presentation and also a panel discussion.

Following that, we'll have the Q&A. So on the screen is the HUTCHMED development portfolio. HUTCHMED is dedicated to innovation and bringing our innovations to patients worldwide. Today's focus is

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot